Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 7:03 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–17 of 17 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Kisspeptin Clear all

Conditions: Reproductive Disorder, PCOS, Polycystic Ovary Syndrome
Interventions: kisspeptin 112-121; Drug
Lead sponsor: Stephanie B. Seminara, MD; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hypogonadotropic Hypogonadism, Kallmann Syndrome, GnRH Deficiency, PCOS, Polycystic Ovarian Syndrome, Hyperprolactinemia
Interventions: kisspeptin 112-121, GnRH; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 256 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Insulin, Glucose, Healthy Volunteers, Women, Pregnancy
Interventions: Kisspeptin-10, mixed meal tolerance test; Drug · Other
Lead sponsor: Stephanie B. Seminara, MD; Other
Eligibility: 18 Years to 40 Years · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hypogonadotropic Hypogonadism, Healthy Postmenopausal Women, Agonadism
Interventions: kisspeptin 112-121, GnRH; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 60 Years
Enrollment: 96 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Delayed Puberty, Kallmann Syndrome, Hypogonadotropic Hypogonadism, GnRH Deficiency
Interventions: kisspeptin 112-121, GnRH; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 12 Years to 17 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hypogonadotropic Hypogonadism
Interventions: kisspeptin 112-121, GnRH; Drug
Lead sponsor: Stephanie B. Seminara, MD; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Metabolic Diseases
Interventions: Oral Glucose Tolerance Test, Kisspeptin, Placebo; Diagnostic Test · Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hyperprolactinemia, Hypogonadism
Interventions: Kisspeptin 112-121, GnRH; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hypogonadotropic Hypogonadism
Interventions: kisspeptin 112-121, leuprolide acetate; Drug
Lead sponsor: Stephanie B. Seminara, MD; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hypogonadotropic Hypogonadism
Interventions: Kisspeptin 112-121, Naloxone, GnRH; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 75 Years
Enrollment: 61 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Reproductive Disorder
Interventions: kisspeptin 112-121, GnRH; Drug
Lead sponsor: Stephanie B. Seminara, MD; Other
Eligibility: 18 Years to 55 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Metabolic Disease
Interventions: Hyperglycemic Clamp, Kisspeptin-10, Placebo; Diagnostic Test · Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 40 Years · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Reproductive Disorder, Neurodegeneration, SARS-CoV 2, Long COVID
Interventions: Kisspeptin 112-121; Drug
Lead sponsor: Stephanie B. Seminara, MD; Other
Eligibility: 18 Years to 60 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hypothalamic Amenorrhea, Hypogonadotropic Hypogonadism
Interventions: Kisspeptin 112-121; Drug
Lead sponsor: Stephanie B. Seminara, MD; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hypogonadotropic Hypogonadism, Reproductive Disorder, Kallmann Syndrome, Delayed Puberty
Interventions: Not listed
Lead sponsor: Stephanie B. Seminara, MD; Other
Eligibility: 1 Year and older
Enrollment: 854 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hypothalamic Amenorrhea, Hypogonadotropic Hypogonadism
Interventions: kisspeptin 112-121; Drug
Lead sponsor: Stephanie B. Seminara, MD; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Low Testosterone
Interventions: TAK-448, TAK-448 Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 60 Years and older · Male only
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Search by objective public record fields.

Dampening the Reproductive Axis With Continuous Kisspeptin

Kisspeptin Administration in the Adult

Evaluation of Kisspeptin Glucose-Stimulated Insulin Secretion With Physiologic Mixed Meal Tolerance

Elucidating Kisspeptin Physiology by Blocking Kisspeptin Signaling

Kisspeptin in the Evaluation of Delayed Puberty

Prolonged Pulsatile Kisspeptin Administration in Hypogonadotropic Hypogonadism

Evaluation of Kisspeptin Glucose-Stimulated Insulin Secretion With Oral Glucose Tolerance Test

Administration of Kisspeptin in Patients With Hyperprolactinemia

Kisspeptin Administration Subcutaneously to Patients With IHH

Neuropeptides in Human Reproduction

Recall by Genotype: Neuropeptide Stimulation

Evaluation of Kisspeptin Stimulated Insulin Secretion With Hyperglycemic Clamp

Kisspeptin to Quantify GnRH Neuronal Function in Health and Disease

Kisspeptin Administration Subcutaneously to Patients With Reproductive Disorders

The Molecular Basis of Inherited Reproductive Disorders

Kisspeptin Administration Subcutaneously to Patients With Hypothalamic Amenorrhea

Effects of TAK-448 in Middle-aged and Older Men With Low Testosterone